Growth Hormone

Sermorelin: The First-Generation GHRH Analog



Sermorelin: The First-Generation GHRH Analog

Growth Hormone
Persona: The Original Signal

Blog / Growth Hormone / Sermorelin

Sermorelin: The First-Generation GHRH Analog

The Original Signal · Growth Hormone

Sermorelin is a 29-amino acid synthetic analog of growth hormone-releasing hormone (GHRH) — the first GHRH peptide to be studied clinically. It represents the baseline from which all subsequent GHRH analogs (CJC-1295, Tesamorelin, Mod GRF 1-29) were developed.

What Is Sermorelin?

Sermorelin (GRF 1-29) is a synthetic peptide representing the first 29 amino acids of natural human GHRH. Full-length GHRH is 44 amino acids; research demonstrated that the N-terminal 29 residues contain the complete biological activity for growth hormone release.

Sermorelin acts on the GHRH receptor (GHRH-R) on somatotroph cells in the anterior pituitary, stimulating pulsatile GH release through the G-protein → cAMP → PKA signaling cascade. It was the first GHRH analog to receive FDA approval (as Geref) — for diagnosing GH deficiency in children.

Preserved Feedback Regulation

Key Finding: GHRH-mediated GH release preserves the physiological feedback loop. Rising GH stimulates IGF-1, which feeds back to suppress further GH via somatostatin and direct pituitary inhibition. This self-regulating mechanism reduces the risk of GH excess — unlike exogenous hGH injection.

This preservation of pulsatility and feedback is the core theoretical advantage of the secretagogue approach over direct hGH administration.

The Short Half-Life Problem

Sermorelin’s primary limitation is its ~10-20 minute plasma half-life. DPP-IV enzyme rapidly degrades it, requiring multiple daily doses. This limitation drove the development of every subsequent GHRH analog:

Compound Half-Life Key Modification
Sermorelin ~10-20 min Natural 1-29 sequence
Mod GRF 1-29 ~30+ min 4 amino acid substitutions
CJC-1295 (DAC) ~8 days Substitutions + drug affinity complex
Tesamorelin ~4 hours N-terminal hexenoyl modification

Sermorelin is the “version 1.0” — every subsequent compound improved on its pharmacokinetics while preserving the same GHRH receptor mechanism.

Limitations

Short half-life (~10-20 min) requires multiple daily doses. Limited clinical data for body composition or anti-aging applications in adults. Largely superseded by newer analogs (CJC-1295, Tesamorelin). Dosing requires consideration of somatostatin cycles, sleep architecture, and feeding patterns.

Source: Vance ML. PMID: 2138584

Explore Sermorelin for Your Research

Lyophilized research-grade sermorelin — specifications, purity, and sourcing.

Disclaimer: This article is for informational and research purposes only. Sermorelin is sold as a research peptide and is not FDA-approved for therapeutic use beyond its original diagnostic indication.


Explore Growth Hormone
The Original Signal · Research Use Only
⚠️ For Research Use Only · Not for Human Consumption · © 2026 Choice Peptide Labs
Research Use Only · Not for Human Consumption
⚠️ For Research Use Only · Not for Human Consumption · © 2026 Choice Peptide Labs

Leave a Reply

Your email address will not be published. Required fields are marked *